Guideline on the design and conduct of cystic fibrosis clinical trials: The European Cystic Fibrosis Society–Clinical Trials Network (ECFS-CTN)

Department of Pediatrics, University Hospital of Leuven, Leuven, Belgium.
Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society (Impact Factor: 3.48). 06/2011; 10 Suppl 2:S67-74. DOI: 10.1016/S1569-1993(11)60010-6
Source: PubMed


We describe the rationale for disease specific research networks in general as well as the aims and function of the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN) specifically. The ECFS-CTN was founded in 2009 with the aim of improving the quality and quantity of clinical research in the area of cystic fibrosis (CF) in Europe. A network of 18 clinical trial sites in 8 European countries was established according to uniform state-of-the-art quality criteria. To support the ECFS-CTN in the acquisition, planning and conduct of clinical trials, the network is equipped with a coordinating centre, steering and executive committees, and committees for protocol review, standardization, training and networking as well as a data safety monitoring board. A strong partnership with European CF patient parent organizations aims to increase awareness of the need for efficient clinical research and the participation of patients in clinical trials.

25 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We consider a feedback system whose performance output differs from its measure output and show that, except in special cases, such a system will exhibit a tradeoff between disturbance response and stability robustness. The severity of this tradeoff is governed by a dimensionless plant parameter, and tends to be significant for systems with lightly damped zeros. The results are illustrated with the problem of noise cancellation in an acoustic duct.
    American Control Conference, 2003. Proceedings of the 2003; 07/2003
  • Source
    Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 06/2011; 10 Suppl 2:S1-4. DOI:10.1016/S1569-1993(11)00089-0 · 3.48 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With knowledge of the molecular behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators, respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial Na(+) channel (ENaC) and activators of the Ca(2+)-activated Cl(-) channel TMEM16A. The expertise required to translate small molecules identified in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our ability to provide pertinent biological information using suitable disease models.
    Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 06/2011; 10 Suppl 2(Suppl 2):S129-45. DOI:10.1016/S1569-1993(11)60018-0 · 3.48 Impact Factor
Show more